Sudeep Pharma Ltd Raises Rs 268.5 Crore from Anchor Investors

• India’s all top Mutual Funds like SBI, ICICI Pru, HDFC, Axis, Nippon, Adiya Birla, Bandhan etc have participated in the anchor
• Other Marquee Investors like Mukul Agarwal (Param Capital Sanshi Fund - I), Manjo Garg (Whiteoak) have built-up their position Prashant Jain (3P Investment) is also part of the Anchor book

Mumbai, November 20, 2025: Sudeep Pharma Limited, a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries, has garnered Rs 268.5 crore from anchor investors ahead of its initial public offering that opens for public subscription on November 21. The company informed the bourses that it allocated 45,27,823 equity shares at Rs 593 per share to anchor investors.

Some of the marquee institutions that participated in the anchor include all of India’s top mutual funds – SBI Healthcare Opportunities Fund, HDFC Mutual Fund – HDFC Innovation Fund, HDFC Mutual Fund – HDFC Manufacturing Fund, ICICI Prudential MNC Fund, Nippon Life India Trustee Ltd – A/C Nippon India Flexi Cap Fund, Axis Mutual Fund Trustee Ltd – A/C Axis Mutual Fund A/C Axis Multi Asset Allocation Fund, Whiteoak Capital Flexi Cap Fund, Aditya Birla Sun Life Trustee A/C Aditya Birla Sun Life Small Cap Fund, Mirae Asset Healthcare Fund MIRAH CFD, Motilal Oswal Large Cap Fund, Quant Mutual Fund – QSIF Equity Long Short Fund, 3PIM India Equity Fund, Bandhan Small Cap Fund, UTI Healthcare Fund and Edelweiss Trusteeship A/C – Edelweiss Mutual Fund – Edelweiss Equity Savings Fund.

Amongst other leading institutions that participated in the anchor include Tata AIA Life Insurance – A/C Small Cap Discovery Fund, SBI Life Insurance and Shamyak Investment Private Ltd.

Other marquee investors like Mukul Agarwal (Param Capital – Sanshi Fund - I), Manjo Garg (Whiteoak) have built-up their positions. Prashant Jain (3P Investment) is also part of the Anchor book.

Out of the total allocation of 45,27,823 equity shares to the anchor investors, 36,05,799 were allocated to 14 domestic mutual funds through schemes.

ICICI Securities and IIFL Capital Services Ltd are the book-running lead manager; and MUFG Intime India Private Limited is the registrar of the offer.

IPO Details

The IPO is a combination of a fresh issue for Rs 95 crore and an offer-for-sale for up to shares 13, 490, 726 by the promoter and promoter group selling shareholders, for Rs 800 crore.

The Initial Public Offering (“IPO” or “Issue”) of the Company will open on Friday, November 21, 2025, for subscription and close on Tuesday, November 25, 2025.

The IPO will fetch Rs 895 crore at the upper end of the price band.

Investors can bid for a minimum of 25 Equity Shares and in multiples of 25 Equity Shares thereafter.

The Offer is being made through the book-building process, wherein not more than 50% of the net offer is allocated to qualified institutional buyers, and not more than 15% and 35% of the net offer is assigned to non-institutional bidders and retail individual bidders respectively. 

Company Information

The company is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem. The company leverages its inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in our operations. 

It has established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific. The company is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual available manufacturing capacity of 72,246 metric tons, as of June 30, 2025 (Source: F&S Report). As of the same date, one of its manufacturing Facilities have been approved by the United States Food and Drug Administration (USFDA) for the manufacture of mineral-based ingredients. 

The company’s revenue from operations during the June 2025 quarter was Rs 124.9 crore and its net profit was Rs 28.4 crore

The company’s revenue from operations was Rs 502 crore during FY 25 vis-à-vis Rs 428.7 crore during FY 23.

The company’s net profit was Rs 137 crore during FY 25 vis-à-vis Rs 60.4 crore during FY 23